Back Back
Cell No. : Cell Name
RCB2231 : HS-SY-II  update : 2021/02/26
CommentHuman cell line derived from synovial sarcoma. Application consideration
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Order Form Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, Category I and II, depending on the sort of user institutions and the purposes of use.Please use an appropriate MTA(to see).In case of Restriction "a" or "f", please contact RIKEN BRC( regarding any kind of for-profit use.
Basic information Depositor Sonobe, Hiroshi
Originator Sonobe, Hiroshi
Year of deposit 2002
Animal human < Mammals
Genus Homo
Species sapiens
Tissue lung, pleural effusion
Disease name synovial sarcoma
Classification cancer
Lifespan infinite
Morphology other
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives DMEM (low glucose) + 10% FBS
Antibiotics Free
Passage method 0.25% trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
STR(human) OK
Isozyme LD, NP
deposit info
lot info
Reference information Reference 1
User's Publication 9

To topTop
3502  Sonobe H, Manabe Y, Furihata M, Iwata J, Oka T, Ohtsuki Y, Mizobuchi H, Yamamoto H, Kumano O, Abe S.  Establishment and characterization of a new human synovial sarcoma cell line, HS-SY-II  Lab Invest.  1992  67:498-505  PubMed ID: 1331610

To topTop
User's Publication
13035  Sekita T, Yamada T, Kobayashi E, Yoshida A, Hirozane T, Kawai A, Uno Y, Moriyama H, Sawa M, Nagakawa Y, Tsuchida A, Matsumoto M, Nakamura M, Nakayama R, Masuda M.  Feasibility of Targeting Traf2-and-Nck-Interacting Kinase in Synovial Sarcoma.  Cancers (Basel)  2020    PubMed ID: 32429395
10309  Yamada S, Imura Y, Nakai T, Nakai S, Yasuda N, Kaneko K, Outani H, Takenaka S, Hamada K, Myoui A, Araki N, Ueda T, Itoh K, Yoshikawa H, Naka N.  Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.  BMC Cancer  2017  17:334  PubMed ID: 28511645
9547  Yasui H, Imura Y, Outani H, Hamada K, Nakai T, Yamada S, Takenaka S, Sasagawa S, Araki N, Itoh K, Myoui A, Yoshikawa H, Naka N.  Trabectedin is a promising antitumour agent for synovial sarcoma.  J Chemother  2016  28:417-24  PubMed ID: 27077926
9557  Sakurai T, Yoshiga D, Ariyoshi W, Okinaga T, Kiyomiya H, Furuta J, Yoshioka I, Tominaga K, Nishihara T.  Essential role of mitogen-activated protein kinases in IL-17A-induced MMP-3 expression in human synovial sarcoma cells.  BMC Res Notes  2016  9:68  PubMed ID: 26850593
9653  Kawano S, Asano M, Adachi Y, Matsui J.  Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma.  Anticancer Res.  2016  36:1553-61  PubMed ID: 27069131
9751  Kawano S, Grassian AR, Tsuda M, Knutson SK, Warholic NM, Kuznetsov G, Xu S, Xiao Y, Pollock RM, Smith JS, Kuntz KK, Ribich S, Minoshima Y, Matsui J, Copeland RA, Tanaka S, Keilhack H.  Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.  PLoS ONE  2016  11:e0158888  PubMed ID: 27391784
10919    Antitumor activities of BIBF 1120, BI 860585, and BI 836845 in preclinical models of sarcoma  Integr Mol Med  2016  3: 755-760 
7359  Mikami T, Kurose A, Javed F, Takeda Y.  Detection of Rare Variant of SS18-SSX1 Fusion Gene and Mutations of Important Cancer-Related Genes in Synovial Sarcoma of the Lip: Gene Analyses of a Case and Literature Review.  J. Oral Maxillofac. Surg.  2015  73:1505-15  PubMed ID: 25959879
8002  Hisaoka M, Matsuyama A, Nagao Y, Luan L, Kuroda T, Akiyama H, Kondo S, Hashimoto H.  Identification of altered MicroRNA expression patterns in synovial sarcoma.  Genes Chromosomes Cancer  2011  50:137-45  PubMed ID: 21213367

Back Back Return Top Page